The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...

Patients with diabetes or obesity receiving GLP-1 RAs are unlikely to experience an increase in the already low rates of ...

Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...

Continuing GLP-1 RA use through surgery increases risk for surgical complications including aspiration and conversion to intubation ...

Investigating GLP-1 RAs reveals their impact on women's health, addressing metabolic disorders, reproductive health, and ...

Patients who continued Ozempic through total joint arthroplasty had the highest risk for complications. (HealthDay News) — Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment ...

GLP-1 RA use is associated with better graft and patient survival among kidney transplant recipients with diabetes.

Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications, according to a study presented at the annual ...

GLP-1 RA use was associated with significantly lower risk of certain cancers compared with metformin use and insulin use.